Phase I Trial of Ruxolitinib Plus Fostamatinib for the Treatment of Steroid Refractory Chronic Graft versus Host Disease
Clinical Trial Grant
Awarded By
Rigel Pharmaceuticals, Inc.
Start Date
July 23, 2024
End Date
July 31, 2029
Awarded By
Rigel Pharmaceuticals, Inc.
Start Date
July 23, 2024
End Date
July 31, 2029